

CURRICULUM VITAE

Date Prepared: June 27, 2007

Name (complete with degrees): James Joseph Vredenburgh

Primary academic appointment: Associate Professor of Medicine

Primary academic department (not DUAP): Department of Medicine

Secondary appointment (if any) - (department): Department of Surgery/Division of Neurosurgery

Present academic rank and title (if any): Associate Professor of Medicine
Duke University Medical Center

Date and rank of first Duke Faculty appointment: Assistant Professor of Medicine
(July 1, 1990)

Medical Licensure: Connecticut
New Hampshire
Vermont
North Carolina

Date of License (Month/Day/Year): North Carolina (May 10, 1990)

Specialty certification(s) and dates (Month/Day/Year):
Board Certified in Internal Medicine (09/13/1986)
Board Certified in Hematology (11/01/1988)
Board Certified in Medical Oncology (11/07/1989)

Date of birth: February 17, 1957 **Place (include city/state/country):** Mount Kisco, New York

Citizen of: United States

Education:	<u>Institution</u>	<u>Date.(Year)</u>	<u>Degree</u>
High School Diploma	Horace Greeley HS Chappaqua, NY	1975	High School
College Psychology	University of Virginia Charlottesville, VA	1979	B.A.,
Graduate or Professional School	University of Vermont Burlington, VT	1983	MD

Scholarly Societies (Alpha Omega Alpha, Sigma Xi, Phi Beta Kappa; etc.):

American Society of Clinical Oncology (ASCO), 1992
American Society of Hematology (ASH), 1992
American Society of Blood and Marrow Transplantation, 1992
International Society for Hematotherapy and Graft Engineering, 1993
Society of Neuro-Oncology

Professional Training and Academic Career (chronologically, beginning with first postgraduate position):

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
St. Francis Hospital and Medical Ctr. Hartford, CT	Residency	1983-86
Dartmouth-Hitchcock Medical Ctr. Hanover, NH	Fellowship	1986-90
Dartmouth Medical School Hanover, NH	Instructor in Medicine	1986-90
Dartmouth Medical School Hanover, NH	Associate in Medicine	1990
Duke University Medical Center Durham, NC	Assistant Professor	1990-96
Duke University Medical Center Durham, NC	Associate Professor	1996-present

PUBLICATIONS:

Refereed Journals:

1. Ramsay A, **Vredenburg J**. Recognition of alcoholism among patients with psychiatric problems in a family practice clinic. *J Family Practice* 17:829, 1983.
2. **Vredenburg JJ**, McIntyre OR, Cornwell CG III, Ball ED, Cornell JC, Mills LE, O'Donnell JF. Mitoxantrone in the treatment of relapsed or refractory acute non-lymphocytic leukemia. *Med & Ped Oncol* 16(3):187-189, 1988.
3. Ball ED, **Vredenburg J**, Mills LE, Cornwell GC, Schwarz L, Howell AL, Troy K. Autologous bone marrow transplantation for acute myelogenous leukemia following *in vitro* treatment with neuraminidase and monoclonal antibodies: A case report. *Bone Marrow Transplantation* 6(4):277-280, 1990.
4. **Vredenburg JJ**, Ball ED. Elimination of small cell carcinoma of the lung from

- human bone marrow by monoclonal antibodies and immunomagnetic beads. *Cancer Res* 50(22):7216-7220, 1990.
5. **Vredenburgh JJ**, Simpson W, Memoli VA, Ball ED. Reactivity of anti-CD15 monoclonal antibody PM-81 with breast cancer and elimination of breast cancer cells from human bone marrow by PM-81 and immunomagnetic beads. *Cancer Res* 51(9):2451-2455, 1991.
 6. Wurster-Hill D, **Vredenburgh JJ**, Mills LE, Davis BH, Ball ED. Isodicentric chromosome 18q as sole abnormality in a histologically normal bone marrow from a patient with diffuse large-cell non-Hodgkin's lymphoma. *Cancer Genet & Cytogenet* 54(2):233-237, 1991.
 7. Ball ED, Powers FJ, **Vredenburgh JJ**, Heath CA, Converse AO. Purging of small cell lung cancer cells from bone marrow using immunomagnetic beads and a flow through device. *Bone Marrow Transplantation* 8(1):35-40, 1991.
 8. Bast RC Jr, Boyer CM, Berchuck A, Xu FJ, Wu S, Lidor Y, Maier LA, Crews JR, Ross M, **Vredenburgh JJ**, Shpall EJ, Peters WP. New strategies for the management of ovarian and breast cancer based on biology and pharmacology. *Cancer Chemotherapy: Challenges for the Future* 7:3-20, 1992.
 9. Marks LB, Halperin EC, Prosnitz LR, Ross M, **Vredenburgh JJ**, Rosner GL, Peters WP, and CALGB. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with >10 axillary lymph nodes. *Int J Radiation Oncology Biol Phys* 23(5):1021-1026, 1992.
 10. Peters WP, Drago S, Tepperberg M, **Vredenburgh JJ**. Collection, cryopreservation and use of peripheral blood progenitor cells primed with colony stimulating factor. In: *Marrow Transplantation: Practical and Technical Aspects of Stem Cell Reconstitution*. Eds: Sacher RA and AuBuchon JP. Arlington, VA: American Association of Blood Banks, pp. 51-67, 1992.
 11. Peters WP, Rosner G, Ross M, **Vredenburgh J**, Meisenberg B, Gilbert C, Kurtzberg J. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. *Blood* 81(7):1709-1719, 1993.
 12. Peters WP, Ross M, **Vredenburgh JJ**, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. *J Clinical Oncology* 11(6):1132-1143, 1993.
 13. Peters WP, Ross M, **Vredenburgh J**, Hussein A, Meisenberg B, Gilbert C, Petros W,

Kurtzberg J. Role of cytokines in autologous bone marrow transplantation. *Hematology/Oncology Clinics of North America* 7:737-747, 1993.

14. Meisenberg B, Ross M, **Vredenburgh JJ**, Jones R, Shpall EJ, Seigler HF, Coniglio DM, Wu K, Peters WP. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node positive malignant melanoma. *J Nat Cancer Inst* 85(13):1080-1085, 1993.
15. Gilbert C, Meisenberg B, **Vredenburgh J**, Ross M, Hussein A, Perfect J, Peters WP. Sequential prophylactic Ciprofloxacin and Rifampin and empiric once daily Vancomycin and aminoglycoside for neutropenic fever after high-dose chemotherapy and autologous bone marrow support. *J Clinical Oncology* 12(5):1005-1011, 1994.
16. Thel MC, Ciaccia D, **Vredenburgh JJ**, Peters W, Corey GR. Clostridium septicum abscess in hepatic metastases: Successful medical management. *Bone Marrow Transplant* 13(4):495-496, 1994.
17. Marks L, Rosner GL, Prosnitz LR, Ross M, **Vredenburgh JJ**, Peters WP. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. *Cancer* 74(11):2964-2971, 1994.
18. Meisenberg B, Lassiter M, Hussein A, Ross M, **Vredenburgh JJ**, Peters WP. Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. *Bone Marrow Transplant* 14(2):287-291, 1994.
19. Mudad R, **Vredenburgh J**, Paulson EK, Ross M, Meisenberg B, Hussein A, Peters WP. A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis. *Cancer* 74(4):1360-1366, 1994.
20. Ghalia AA, Silva O, **Vredenburgh JJ**, Bast RC Jr. Advances in the detection of marrow micrometastases in breast cancer. *Cancer Research, Therapy and Control* 4:43-47, 1994.
21. Peters WP, Ross M, **Vredenburgh J**, Hussein A, Rubin P, Dukelow K, Cavanaugh C, Beauvais R, Kasprzak S. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. *Seminars in Oncology* 21(4) (Suppl 7):25-31, 1994.
22. Young ST, Paulson EK, Washington K, Gulliver DJ, **Vredenburgh JJ**, Baker ME. CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: Findings simulating cirrhosis. *AJR* 163(6):1385-1388, 1994.
23. Hussein AM, Ross M, **Vredenburgh J**, Meisenberg B, Hars V, Gilbert C, Petros WP, Coniglio D, Kurtzberg J, Rubin P, Peters WP. Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim),

Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. *European J Haematol*, 55(5):348-356, 1995.

24. **Vredenburgh JJ**, Peters WP, Rosner G, De Sombre K, Johnston WW, Kamel A, Wu K, Bast RC Jr. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high dose chemotherapy: The role of induction chemotherapy. *Bone Marrow Transplantation*, 16(6): 815-821, 1995.
25. Cartee L, Petros WP, Rosner G, Gilbert C, Moore S, Affronti ML, Hoke J, Hussein AM, Ross M, Rubin P, **Vredenburgh JJ**, Peters WP. Evaluation of GM-CSF mouthwash prevention of chemotherapy-induced mucositis: A randomized, double-blind, dose ranging study. *Cytokine* 7(5): 471-477, 1995.
26. Hussein AM, Petros WP, Ross M, **Vredenburgh JJ**, Affronti ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Pearson D, Berry DA, Peters WP. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral blood progenitor cells in patients with advanced malignancies. *Cancer Chemotherapy and Pharmacology*, 37: 561-568, 1996.
27. Ingram SS, Samulski T, Dodge R, Prosnitz LR, Peters WP, **Vredenburgh JJ**. The effects of hyperthermia in bone marrow purging of breast cancer. *Int Journal of Hyperthermia*, 12 (1) 21-29, 1996.
28. Cohen A, Tepperberg M, Waters-Pick B, Coniglio D, Perfect J, Peters WP, Gilbert C, Morgan C, **Vredenburgh JJ**. The significance of microbial cultures of the hematopoietic support for patients receiving high-dose chemotherapy. *Journal of Hematotherapy*, 5(3):289-294, 1996.
29. Rubin P, Hulette C, Khawly JMI, Elkordy M, Hussein A, **Vredenburgh JJ**. Ocular toxicity following high dose chemotherapy and autologous bone marrow transplantation: Case report and pathological correlation. *Bone Marrow Transplantation*, 18(1):253-256, 1996.
30. **Vredenburgh JJ**, Silva O, Tyer CL, DeSombre K, Cook M, Layfield L, Peters WP, Bast RC Jr. A comparison of immunohistochemistry, two-color immunofluorescence and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. *Journal of Hematotherapy*, 5(1):57-62, 1996.
31. Petros WP, Rosner G, Rabinowicz J, Gilbert C, Coniglio D, **Vredenburgh JJ**, Ross M, Peters WP. The pharmacologic effects of recombinant, human colony-stimulating factors and their modulation by theophylline. *Pharmacotherapy*, 16(5):742-748, 1996.
32. Fisher DC, Sherrill, G. Bradley, Hussein A, Rubin P, **Vredenburgh JJ**, Elkordy M, Ross M, Peters WP. Thrombotic microangiopathy as a complication of high-

- dose chemotherapy for breast cancer. *Bone Marrow Transplantation*, 18(1):193-198, 1996.
33. Tyer CL, **Vredenburgh JJ**, Heimer M, Peters WP, Bast RC Jr. Breast cancer cells are effectively purged from peripheral blood progenitor cells using an immunomagnetic technique. *Clin Cancer Res*, 2(1):81-86, 1996.
 34. **Vredenburgh JJ**, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Peters WP, Bast RC Jr. The significance of tumor contamination in the bone marrow from high risk primary breast cancer patients treated with high dose chemotherapy and hematopoietic support. *Biology of Blood and Marrow Transplantation* 3(2):91-97, 1997.
 35. Elkordy M, Crump M, **Vredenburgh J**, Petros WP, Hussein A, Rubin P, Ross M, Gilbert C, Modlin C, Meisenberg B, Coniglio D, Rabinowitz J, Laughlin M, Kurtzberg J, Peters WP. A phase I trial of recombinant human interleukin-1-beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. *Bone Marrow Transplantation*, 19(4):315-322, 1997.
 36. Arata M, Provenzale J, **Vredenburgh JJ**. Cytomegalovirus encephalomyelitis. MR imaging findings documenting response to ganciclovir therapy. *AM J Roentgenol* 171(1):103-105, 1998.
 37. Laughlin M, McGaughey D, Crews J, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, **Vredenburgh JJ**. Secondary myelodysplasia and acute leukemia in breast cancer patients following autologous bone marrow transplant. *J Clin Oncol* 16(3):1008-1012, 1998.
 38. Wilczynski SW, Erasmus JJ, Petros WP, **Vredenburgh JJ**, Folz RJ. Delayed pulmonary toxicity syndrome (DPTS) following high-dose chemotherapy and bone marrow transplantation for breast cancer. *Am J Respir Crit Care Med* 157(2): 565-573, 1998.
 39. Fisher DC, **Vredenburgh JJ**, Petros WP, Hussein A, Berry DA, Elkordy MA, Rubin P, Gilbert CG, Peters WP. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. *Bone Marrow Transplantation* 21(2):117-122, 1998.
 40. Gilbert CJ, Petros WP, **Vredenburgh JJ**, Hussein A, Ross M, Rubin P, Fehdrau R, Cavanaugh C, Berry D, McKinstry C, Peters WP. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high dose chemotherapy for breast cancer. *Cancer Chemotherapy Pharmacol* 42(6):497-503, 1998.
 41. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, **Vredenburgh JJ**, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-

occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. *Blood* 92(3):737-744, 1998.

42. **Vredenburgh JJ**, Hussein A, Fisher D, Hoffman M, Elkordy M, Rubin P, Gilbert C, Kaye JA, Dykstra K, Loewy J, Peters WP. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. *Biology of Blood and Marrow Transplantation* 4:134-141, 1998.
43. Lundell BI, **Vredenburgh JJ**, Tyer C, DeSombre K, Smith AK. Ex vivo expansion of bone marrow from breast cancer patients: reduction in tumor cell content through passive purging. *Bone Marrow Transplant.* 22(2):153-159, 1998.
44. **Vredenburgh J**, Fishman R, Coniglio D, Matters L, Elkordy M, Ross M, Hussein A, Rubin P, Gilbert C, Petros W, Peters WP. The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. *Amer J Clin Oncol* 21(6):543-547, 1998.
45. Abruzzese E, Radford JE, Miller JS, **Vredenburgh JJ**, Rao PN, Pettenati MJ, Cruz JM, Perry JJ, Amadori S, Hurd DD. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. *Blood* 94(5):1814-1819, 1999.
46. Carter DL, Marks LB, Bean JM, Broadwater G, Hussein A, **Vredenburgh JJ**, Peters WP, Prosnitz LR. Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue. *J Clin Oncol* 17(3):887-893, 1999.
47. Rizzieri DA, **Vredenburgh JJ**, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. *J Clin Oncol* 17(10):3064-3074, 1999.
48. Morse MA, **Vredenburgh JJ**, Lysterly HK. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. *J Hematother Stem Cell Res.* 8(6):577-584, 1999.
49. Hara M, McAdams HP, **Vredenburgh JJ**, Herndon JE, Patz EF Jr. Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer. *Am J Roentgenology* 173(5):1341-1344, 1999.
50. Bearman S, **Vredenburgh J**, Cagnoni P, Shpall E, Nieto Y, Ross M, Peters W, Jones R. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. *Bone Marrow Transplant* 24(5):491-495, 1999.

51. Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, **Vredenburgh J**, Chao NJ, Bearman SI, Jones RB. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. *Clinical Cancer Research* 5(11):3425-3431, 1999.
52. Selzner M, Morse MA, **Vredenburgh JJ**, Meyers WC, Clavien PA. Liver metastases from breast cancer: Long-term survival after curative resection. *Surgery* 127:383-389, 2000.
53. Nieto Y, Champlin RE, Wingard JR, **Vredenburgh JJ**, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. *Biol Blood Marrow Transplant* 6(5):476-495, 2000.
54. Bhalla KS, Wilczynski SW, Abushamaa AM, Petros WP, McDonald CS, Loftis JS, Chao NJ, **Vredenburgh JJ**, Folz RJ. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. *Am J Respir Crit Care Med* 161(1):17-25, 2000.
55. Bolwell B, **Vredenburgh J**, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. *Bone Marrow Transplantation* 26:141-145, 2000.
56. McGaughey DS, Nikcevich DA, Long GD, **Vredenburgh JJ**, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz RF, Chao NJ. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. *Biology of Blood and Marrow Transplantation* 7(5):274-278, 2001.
57. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzieri D, **Vredenburgh JJ**, Bentley RC. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. *J Clin Oncol* 19(6):1698-1706, 2001.
58. Maddox L, Long GD, **Vredenburgh JJ**, Folz RJ. Rhizopus presenting as an endobronchial obstruction following bone marrow transplant. *Bone Marrow Transplant* 28(6):634-636, 2001.
59. Rizzieri DA, Long GD, **Vredenburgh JJ**, Gasparetto C, Morris A, Stenzel TT, Davis P, Chao NJ. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. *Blood* 98(12):3486-3488, 2001.
60. Petros WP, Broadwater G, Berry D, Jones RB, **Vredenburgh JJ**, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with

primary breast cancer. *Clin Cancer Res* 8(3):698-705, 2002.

61. McCune SL, Gockerman JP, Moore JO, DeCastro CM, Bass AJ, Chao NJ, Long GD, **Vredenburgh JJ**, Gasparetto C, Adams D, Payne N, Rizzieri DA. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphatic leukemia. *Leuk Lymphoma* 43(5):1007-1011, 2002.
62. Chao NJ, Liu CX, Rooney B, Chen BJ, Long GD, **Vredenburgh JJ**, Morris A, Gasparetto C, Rizzieri DA. Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. *Biol of Blood and Marrow Transpl* 8:249-256, 2002.
63. Gasparetto C, Gasparetto M, Morse M, Rooney B, **Vredenburgh JJ**, Long GD, Rizzieri DA, Loftis J, Chao NJ, Smith C. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3 ligand and G-CSF or GM-CSF. *Cytokine* 18(1):8-19, 2002.
64. Lind PA, Marks LB, Jamieson TA, Carter DL, **Vredenburgh JJ**, Folz RJ, Prosnitz LR. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue. *Cancer* 94(11):2821-2829, 2002.
65. Garantziotis S, Bhalla KS, Long GD, **Vredenburgh JJ**, Folz RJ. Fatal re-expansion pulmonary edema associated with increased lung IL-8 levels following high-dose chemotherapy and autologous stem cell transplant. *Respiration* 69(4):351-354, 2002.
66. Morse MA, Rizzieri D, Stenzel TT, Hobeika AC, **Vredenburgh JJ**, Chao N, Clay TM, Mosca PJ, Lyerly HK. Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. *J Hematother Stem Cell Res* 11(4):659-668, 2002.
67. Richardson PG, Murakami C, Jin Z, Warren DL, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer RJ, Spitzer TR, Avigan D, Bearman SI, Martin PL, Kurtzberg J, **Vredenburgh J**, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. *Blood* 100(13):4337-4343, 2002.
68. Stuart MJ, Peters WP, Broadwater G, Hussein A, Ross M, Marks LB, Folz RJ, Long GD, Rizzieri D, Chao NJ, **Vredenburgh JJ**. High dose chemotherapy and hematopoietic support for patients with high risk primary breast cancer and involvement of four to nine lymph nodes. *Biology of Blood and Marrow Transplantation* 8(12):666-673, 2002.
69. Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin E, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon R, Friedman A, Friedman H, Kurtzberg J, **Vredenburgh J**, Martin P. High-dose chemotherapy with autologous stem

cell rescue in children and adults with newly diagnosed pineoblastomas. Accepted for publication, *Journal of Clinical Oncology*, 121(11):2187-2191, 2003.

70. Rizzieri D, Ibom V, Moore JO, DeCastro C, Rosner G, Adams D, Foster T, Payne N, Thompson M, **Vredenburgh JJ**, Gasparetto C, Long G, Chao N, Gockerman J. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. *Clinical Cancer Research*, 9(2):663-668, 2003.
71. Long GD, Laughlin M, Madan b, Kurtzbrg J, Gasparetto C, Morris A, Rizzieri D, Smith C, **Vredenburgh J**, Halperin EC, Broadwat G, Niedzwiecki D, Chao NJ. Unrelated umbilical cord blood transplantation in adult patients. *Biology of Blood and Marrow Transplantation* 9(12):772-80, 2003.
72. Rizzieri DA, Talbot JT, Long GD, **Vredenburgh JJ**, Gasparetto C, Smith CS, Colvin MO, Adams D, Morris A, Dodge R, Loftis J, Waters-Pick B, Reese M, Carawan H, Koh LP, Chao NJ. 4-hydroperoxycyclophosphamide-purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia. *Biol Blood Marrow Transplant* 9(3):183-8, 2003.
73. Gottfredsson M, **Vredenburgh JJ**, Xu J, Schell WA, Perfect JR. Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. *Cancer* 98(1):24-30, 2003.
74. Reardon DA, Quinn JA, Rich JN, Gururangan S, **Vredenburgh J**, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. *Neuro-Oncology* 6(2):134-44, 2004.
75. Snyder MJ, Stenzel TT, Buckley PJ, Lagoo AS, Rizzieri DA, Gasparetto C, **Vredenburgh JJ**, Chao NJ, Gong JZ. Post-transplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation. *Am J Surg Pathol* 28(6):794-800, 2004.
76. Badruddoja MA, **Vredenburgh J**, Peery TS, Reardon DA. Kluver-Bucy syndrome related to glioma. *Neurology* 63(1):184, 2004.
77. Nieto Y, **Vredenburgh JJ**, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Baron AE, Jones RB. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. *Clin Cancer Res*, 10(21):7136-43, 2004.
78. Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, **Vredenburgh JJ**, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. *Cancer* 100(11):2408-14, 2004.

79. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, **Vredenburgh J**, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE 2nd, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. *Neuro-Oncology* 6(2):145-53, 2004.
80. Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, **Vredenburgh J**, Proia A, Harris LN. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. *Clin Cancer Res*, 10(12 pt 1):4083-4088, 2004.
81. Reardon DA, Quinn JA, Rich JN, Gururangan S, **Vredenburgh J**, Sampson JH, Provenzale JM, Walker A, Perry T, Badruddoja M, Tourt-Uhlig S, Herndon JE II, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Friedman AH, Bigner DD, Friedman HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. *Neuro-Oncology*, 6(2):134-144, 2004.
82. Bhagat R, Rizzieri DA, **Vredenburgh JJ**, Chao NJ, and Folz RJ. Pulmonary sarcoidosis following stem cell transplantation: Is there more than a chance occurrence? *Chest*. 126(2):642-644, 2004.
83. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancy JE, McLendon RE, Kao JC, Stenzel TT, Rasheed BKA, Tourt-Uhlig SE, Herndon II JE, **Vredenburgh JJ**, Sampson JH, Friedman AH, Bigner DD, and Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. *J Clin Oncol*, 22(1):133-142, 2004.
84. Reardon DA, Quinn JA, Rich, JN, Desjardins A, **Vredenburgh J**, Gururangan S, Badruddoja M, McLendon R, Provenzale J, Herndon II JE, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Phase 1 Trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. *Cancer*. 104(7):1478-1486, 2005.
85. Reardon D, Quinn JA, **Vredenburgh JJ**, Rich JN, Gururangan S, Badruddoja M, Herndon II JE, Dowell JM, Friedman AH, Friedman HS. Phase II trial of Irinotecan plus celecoxib in adults with recurrent malignant glioma. *Cancer* 103(2):329-338, 2005.
86. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, **Vredenburgh J**, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancy JE, Maxwell J, Tourt-Uhlig S, Herndon II J, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O⁶-benzylguanine for patients with recurrent or progressive. *J Clin Onco*, 23(28):7178-7187, 2005.
87. Reardon DA, Egorin MJ, Quinn JA, Rich Sr, JN, Gururangan I, **Vredenburgh J**, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon II, JE, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson

- JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of Imatinib Mesylate Plus Hydroxyurea in Adults with Recurrent Glioblastoma Multiforme. *J Clin Onc*, 23(36):9359-9368, 2005.
88. Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, **Vredenburgh J**, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. *Cancer*, 104(8):1580-1589, 2005.
89. Petros WP, Hopkins PJ, Spruill S, Broadwater G, **Vredenburgh JJ**, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. *J Clin Oncol*, 23(25):6117-6125, 2005.
90. Peters WP, Rosner GL, **Vredenburgh JJ**, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. *J Clin Oncol*, 23(10):2191-2200, 2005.
91. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon, II, JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, **Vredenburgh J**, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao X-G, Zalutsky MR, Bigner DD. Salvage Radioimmunotherapy with Murine ¹³¹I-Labeled Anti-Tenascin Monoclonal Antibody 81C6 for Patients with Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. *J Clin Onco*, 24(1):115-122, 2006.
92. Reardon DA, Quinn JA, **Vredenburgh J**, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon II JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich, JN. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. *Clin Ca Res*. 12(3pt 1):860-868, 2006.
93. **Vredenburgh J**, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein A, Rizzieri D, Marks LB, Gilbert C, Affronti ML, Moore S, McDonald C, Petros WP, Peters WP. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared to intensive standard-dose chemotherapy alone. *Biology of Blood and Marrow Transplantation*, 12(2):195-203, 2006.
94. Gururangan S, Brashears J, Watral MA, McLaughlin CA, Provenzale J, Coleman RE, Halperin EC, Quinn J, Reardon D, **Vredenburgh J**, Friedman A, Friedman HS. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. *Neuro-oncology*, 77(2):207-212, 2006.

95. **Vredenburgh J**, Madan B, Coniglio D, Ross M, Broadwater G, Niedzwiecki D, Edwards J, Marks L, Vandemark R, McDonald C, Peters MLW. A randomized phase III comparative trial of immediate consolidation with high dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. *Bone Marrow Transplantation*, 37(11):1009-1015, 2006.
96. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, **Vredenburgh JJ**, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel human IgG2b/murine chimeric antitenascin in monoclonal antibody construct radiolabeled with ¹³¹I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. *J Nucl Med*, 47(6):912-918, 2006.
97. Huang YC, O'Brien SR, **Vredenburgh J**, Folz RJ, Macintyre NR. Intra-breath analysis of carbon monoxide uptake during exercise in patients at risk for lung injury. *Respir Med*, 100(7):1226-1233, 2006.
98. Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn J, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, **Vredenburgh JJ**. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. *Neuro-Oncology*, 9(1):70-74, 2007.
99. Meiri E, Jhangiani H, **Vredenburgh JJ**, Barbato LM, Carter FJ, Yang H-M, Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. *Curr Med Res Opin*, 23(3):533-543, 2007.
100. Gururangan S, Fisher MJ, Allen JC, Herndon 2nd JE, Quinn JA, Reardon DA, **Vredenburgh JJ**, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. *Neuro-Oncology*, 9(2):161-168, 2007.
101. Sathornsumetee S, Rich JN, **Vredenburgh JJ**, Reardon DA, Desjardins A. Neurofibromatosis type 2. *Neurology*, 68(13):E14, 2007.
102. Desjardins A, Quinn JA, **Vredenburgh JJ**, Sathornsumetee S, Friedman AH, Herndon 2nd JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of Imatinib Mesylate and Hydroxyurea for recurrent grade III malignant gliomas. *J Neuro Oncol*, 83(1):53-60, 2007.

103. Badruddoja MA, Keir S, King I, Zeidner J, **Vredenburgh JJ**, Muhlbaier LH, Bigner DD, Friedman HS. Activity of VNP40101M (Cloretazine®) in the treatment of CNS tumor xenografts in athymic mice. *Neuro-Oncology*, 9(1):70-74, 2007.
104. **Vredenburgh J**, Desjardins A, Herndon 2nd JE, Dowell J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of Bevacizumab and Irinotecan in recurrent malignant glioma. *Clin Ca Res*, 13(4):1253-1259, 2007.
105. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horowitz M, Chute J, Smith C, Gong J, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Lu CX, Marshall D, **Vredenburgh JJ**, Gockerman J, Decastro C, Moore J, Chao N. Partially matched, non-myeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution. *J Clin Oncol*, 25(6):690-697, 2007.
106. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, **Vredenburgh JJ**, Rich JN. Molecularly targeted therapy for malignant glioma. *Cancer*, 110(1):13-24, 2007.
107. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, **Vredenburgh J**, Quinn J, Friedman HS. Multi-focal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. *Neuro-Oncology*, In Press, 2007.
108. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon 2nd JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, **Vredenburgh JJ**, Desjardins A, Boulton A, Raynor RH, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-anti-tenascin monoclonal antibody 81C6 to deliver a 44 Gy resection cavity boost. *Neuro-Oncology*, In Press, 2007.
109. **Vredenburgh JJ**, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab and Irinotecan: An Active Regimen against Recurrent Glioblastoma Multiforme. *J Clin Oncol*, In Press, 2007.

Non-Refereed publications:

1. **Vredenburgh JJ**, Peters WP: Commentary on the article, "Bone marrow micrometastases in breast cancer", written by M Osborne and P Rosen. *Oncology* 8:31, 1994.
2. Desjardins A, Rich JN, Quinn JA, **Vredenburgh J**, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel Therapeutic approaches in malignant glioma. *Front Biosci*. 2005 Sept 1, 10:2645-68, 2005.

Books:

1. **Vredenburgh JJ**, Ball ED: Lymphokines and lung cancer. In, Lung Cancer Differentiation, Bernal S, Baylin S, eds. New York: Marcel Dekker, Inc., 1992.
2. **Vredenburgh JJ**. Photographic Case Studies in Surgical Oncology. Diagnostic Tests for Practitioners eds. Clinical Communications, 1993
3. **Vredenburgh JJ**. Photographic Case Studies in Malignant Disease. Diagnostic Tests for the Practitioner. eds. Clinical Communications, 1993.
4. Seraly M, **Vredenburgh J**, Zwas FR. Immunocompromised Patients. A Case Study Approach. eds. Clinical Communications, vol. 1, 1995.
5. Seraly M, Skowron G, **Vredenburgh JJ**, Zwas F. Immunocompromised Patients: A Case Study Approach. eds. Clinical Communications, vol. 2, 1995.
6. **Vredenburgh JJ**, Tyer C, DeSombre K, Broadwater G, Berry D. The Detection and Significance of Tumor Cell Contamination of the Bone Marrow. Autologous Marrow and Blood Transplantation, Proceedings of the Eighth International Symposium, Arlington Texas, Karel A. Dicke and Armond Keating, vol VIII, pg 485, 1195.
7. McGaughey DS, **Vredenburgh JJ**. Myelodysplasia and acute leukemia following high-dose chemotherapy. Current Clinical Oncology: Current Controversies in Bone Marrow Transplantation, Brian J. Bolwell, ed., Humana Press, Totowa, NJ, pp. 261-277, 2000.
8. Vafai D, **Vredenburgh JJ**, Ball ED. Purging of contaminating tumor cells. Hematopoietic Stem Cell Therapy, 1st edition, Edward D. Ball, John Lister and Ping Law, eds. Churchill Livingstone, A Harcourt Health Sciences Company, New York, pp. 322-334, 2000.

OTHER:

Selected Abstracts:

1. **Vredenburgh J**, McIntyre OR, Cornwell GG III, Ball ED, Cornell CJ, Mills LE, O'Donnell JF. Mitoxantrone in the treatment of relapsed and refractory acute non-lymphocytic leukemia. Leukemia 1:287, 1987.
2. **Vredenburgh JJ** and Ball ED. Monoclonal antibodies and immunomagnetic beads eliminate small cell carcinoma of the lung from bone marrow. Proceedings of the American Society of Clinical Oncology 8:224(No. 871), 1989.
3. **Vredenburgh JJ**. The detection of a low percentage of small cell carcinoma of the lung or breast cancer cells in the bone marrow by two-color flow cytometry. Submitted

for presentation at the New England Cancer Society Meeting, 1989.

4. Ball ED, **Vredenburgh JJ**, Crabtree GW. Monoclonal antibodies detect and eliminate breast cancer from bone marrow. UCLA Bone Marrow Transplant Symposia. J Cell Biochem 1990.
5. Powers F, Heath CA, Ball ED, **Vredenburgh JJ**, Converse AO. Separation of tumor cells from bone marrow using immunomagnetic beads. Presented at the Cell Separation Symposium at the ACS Meeting, Boston, Massachusetts, 1990.
6. Simpson WA, **Vredenburgh JJ**, Ball ED, Memoli VA. PM-81 reactivity with normal, fibrocystic and malignant breast tissues. Presented at the United States and Canadian Academy of Pathology Meeting, Boston, Massachusetts, 1990.
7. **Vredenburgh JJ**, Davis B, Ball ED. The detection of low percentages of small cell carcinoma of the lung or breast cancer cells in the bone marrow by two-color flow cytometry. Proceedings of the American Society of Clinical Oncology 9:7 (No. 23), 1990.
8. **Vredenburgh JJ**, Ross M, Dukelow K, Johnson S, Shpall EJ, Jones RB, Bast RC, Peters WP. Intravenous gamma globulin for refractory thrombocytopenia following high-dose alkylating chemotherapy and autologous bone marrow transplantation. Blood 76:410a, 1990.
9. Peterson J, Kirkpatrick G, Ross M, **Vredenburgh J**, Peters WP, Kurtzberg J. Growth factor primed peripheral blood progenitor cells (PBPC) are enriched for hematopoietic progenitor cells (HPC). Proceedings of the American Society of Clinical Oncology 10:78, 1991.
10. Winer EP, Gold DT, Lees J, Affronti ML, Westlund R, Ross M, **Vredenburgh J**, Jones R, Shpall E, Trump DL, Peters WP, Cohen HJ. Quality of life (QL) following high dose chemotherapy with autologous bone marrow support (HDC) in patients with metastatic breast cancer. Proceedings of the American Society of Clinical Oncology 10:62, 1991.
11. Peterson J, Kirkpatrick G, Ross M, **Vredenburgh J**, Peters WP, Kurtzberg J. Growth factor-primed peripheral blood progenitor cells (PBPC) are enriched for hematopoietic progenitor cells (HPC). Proceedings of the American Society of Clinical Oncology 10:78a, 1991.
12. **Vredenburgh JJ**, Ross A, Siegel MD, Ring D, Ross M, Peters WP. Micrometastatic bone marrow involvement in patients with breast cancer and 10 or more positive nodes. Breast Cancer Research and Treatment 19:171(No. 59), 1991.
13. **Vredenburgh J**, Ross M, Kurtzberg J, Coniglio D, Dukelow K, Gilbert C, Peters W: Phase I trial of Interleukin-1-beta (IL-1-beta) following high-dose chemotherapy and autologous bone marrow transplantation (ABMT). Blood 78:6a, 1991.

14. Peters WP, Hussein AM, Kurtzberg J, Ross M, **Vredenburgh J**, Gilbert C, Coniglio D, Dukelow K, Oette D. Use of recombinant human Interleukin-3 (IL-3) in patients (pts) with metastatic breast cancer receiving high-dose chemotherapy (HDC) and chemo-immunologically purged autologous bone marrow transplantation (P-ABMT). *Blood* 78:162a, 1991.
15. Meisenberg B, Ross M, Jones R, **Vredenburgh J**, Seigler H, Peters WP. Adjuvant high-dose combination alkylating agent chemotherapy (HDCAA) with autologous bone marrow support (ABMS) in multi-node positive melanoma. *Proceedings of the American Society of Clinical Oncology* 11:345a, 1992.
16. **Vredenburgh J**, Shpall EJ, Ross M, Meisenberg B, Bast R, Tyer C, Tepperberg M, Eggleston S, Peters WP. Immunopharmacologic bone marrow purging and high-dose chemotherapy with autologous bone marrow support (ABMS) for patients with metastatic breast cancer. *Proceedings of the American Society of Clinical Oncology* 11:58, 1992.
17. Peters WP, Ross M, **Vredenburgh J**, Meisenberg B, Rosner G, Marks L, Mathias B, Henderson C, Hurd D, Budman D, Norton L, Weiss RB. High-dose alkylating agents and autologous bone marrow support (ABMS) for stage II/III breast cancer involving 10 or more axillary lymph nodes (Duke and CALGB 8782). *Proceedings of the American Society of Clinical Oncology* 11:58, 1992.
18. **Vredenburgh JJ**, Ross M, Meisenberg B, Hussein A, Kurtzberg J, Gilbert C, Petros W, Peters WP. A short course of G-CSF for priming of peripheral blood progenitor cells (PBPC). *Blood* 80:291a, 1992.
19. Crump M, Ross M, **Vredenburgh J**, Meisenberg B, Dukelow K, Peters WP. Early toxicity after high-dose therapy and autologous bone marrow transplantation (ABMT) for breast cancer: Implications for outpatient management. *American Society of Hematology 34th Annual Meeting*, *Blood* 80:70a, 1992.
20. Meisenberg B, Affronti M, Ross M, **Vredenburgh J**, Hussein A, Kay J, Peters WP. Recombinant human macrophage colony-stimulating factor (rhM-CSF) after high-dose chemotherapy (HDC) with autologous bone marrow support (ABMS). *Blood* 80:417a, 1992.
21. Gupton C, Rabinowitz J, Petros W, Stuart A, **Vredenburgh J**, Peters WP. Interleukin-3 therapy suppresses endogenous cytokine concentrations following high-dose chemotherapy and autologous bone marrow transplantation (ABMT). *Blood* 80:85a, 1992.
22. Hussein A, **Vredenburgh JJ**, Meisenberg BR, Ross M, Petros WP, Peters WP. Protection against chemotherapy-induced alopecia by minoxidil in the newborn rat animal model. *American Society of Hematology 34th Annual Meeting*. *Blood* 80:450a, 1992.

23. **Vredenburgh J**, Ross M, Meisenberg B, Bast RC Jr, Gilbert C, Lawrence J, Moore S, Affronti M, Coniglio D, Mathias B, Oette D, Peters WP. Use of interleukin-3 (IL-3) and/or GM-CSF in patients with metastatic breast cancer receiving high-dose chemotherapy (HDC) and immunopharmacologically purged (IMP) autologous bone marrow support (P-ABMS). Twenty-Fourth Congress of the International Society of Hematology 24:1, 1992.
24. Peters WP, Ross M, **Vredenburgh J**, Winer E, Rosner G, Meisenberg B, Hussein A. High-dose adjuvant chemotherapy with autologous bone marrow support for high-risk primary breast cancer. International Conference on the Adjuvant Therapy of Cancer, March 10-13, 1993.
25. Ross AA, Cooper BW, Lazarus HM, Peters WP, **Vredenburgh JJ**, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson N, Sweet DS, Di Persio JF, Klumpp TS, Jansen J, Akard L, Copelan E, Kahn DG, Waner NE. Incidence of tumor cell contamination in peripheral blood stem cell (PBSC) collections from breast cancer patients. Proceedings of the American Society of Clinical Oncology 12:69, 1993.
26. **Vredenburgh J**, Ross M, Meisenberg B, Mudad R, Paulson E, Hussein A, Peters WP. Hepatic, splenic and renal candidiasis following high-dose chemotherapy and autologous bone marrow support. Proceedings of the American Society of Clinical Oncology 12:456, 1993.
27. Crump M, Ross M, **Vredenburgh J**, Shpall E, Jones R, Meisenberg B, Peters WP. Phase I/II evaluation of high-dose thiotepa, cisplatin and cyclophosphamide with autologous stem cell rescue for patients with refractory solid tumors. Proceedings of the American Society of Clinical Oncology 12:131, 1993.
28. **Vredenburgh J**, Bast RC Jr, De Sombre K, Johnston W, Peters WP. Detection of tumor cells in the bone marrow or peripheral blood in breast cancer patients with 10 or more positive nodes. Proceedings of the American Association for Cancer Research 34:1130, 1993.
29. Tyer C, **Vredenburgh J**, Bast RC Jr, Peters WP. Two-color immuno-fluorescence improves the detection of tumor cells in the bone marrow. Fourth International Symposium on Purging and Processing 4:81, 1993.
30. **Vredenburgh J**, Ross M, Meisenberg B, Hussein A, Bast RC Jr, Shpall EJ, Tyer C, Heimer M, Tepperberg M, Affronti ML, Moore S, Peters WP. A phase I trial of high-dose chemotherapy and immunopharmacologically purged autologous bone marrow support for patients with metastatic breast cancer. Fourth International Symposium on Purging and Processing 4:23, 1993.
31. **Vredenburgh JJ**, Waters-Pick B, Kurtzberg J, Drago S, Ross M, Hussein A, Peters WP. A single 6-hour (HR) steady state leukapheresis is sufficient for collection of peripheral blood progenitor cells (PBPC) after G-CSF. Blood 82:1381(a), 1993.

32. Hussein A, Ross M, **Vredenburgh JJ**, Meisenberg B, Gilbert C, Petros WP, Coniglio D, Kurtzberg J, Peters WP. Effects of granulocyte-macrophage colony stimulating factor (GM-CSF), Escherichia coli (E. Coli-GM) or yeast (yeast GM) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. *Blood* 82:1156(a), 1993.
33. Drago S, **Vredenburgh J**, Waters-Pick B, Kurtzberg J, Ross M, Meisenberg B, Hussein A, Peters WP. Increased whole blood flow or collection rates increase the yield of G-CSF primed peripheral blood progenitor cells. *American Society for Apheresis* 14:52, 1993.
34. **Vredenburgh J**, Ross M, Hussein A, Rubin P, Coniglio D, Matters L, Dukelow K, Gilbert C, Petros W, Peters WP. A phase I trial of high-dose ifosfamide(I), carboplatin©, and melphalan(M) (ICaM) with hematopoietic support (HS) for advanced metastatic breast cancer (MBC). *Proceedings of ASCO* 13:96, 1994.
35. Elkordy M, Matters L, Coniglio D, Petros W, **Vredenburgh J**, Hussein A, Meisenberg B, Rubin P, Ross M, Peters W. The effect of continuous infusion 5-FU (CI-F) with or without Taxol (T) as induction therapy in Stage IV breast carcinoma (BC). *Proceedings of ASCO* 13:95, 1994.
36. Rubin P, Jaffe GJ, Hussein A, **Vredenburgh J**, Ross M, Peters WP. Ocular toxicity following high-dose chemotherapy and autologous bone marrow transplant. *Proceedings of ASCO* 13:148, 1994.
37. **Vredenburgh J**, Waters-Pick B, Drago S, Affronti ML, Kurtzberg J, Ross M, Hussein A, Rubin P, Elkordy M, Meisenberg B, Peters WP: G-CSF-primed peripheral blood progenitor cells (PBPCs) collected in the steady state are superior to G-CSF-primed PBPCs collected on the rebound from chemotherapy. *Blood* 84:416(a), 1994.
38. Peters WP, Berry D, **Vredenburgh JJ**, Hussein A, Rubin P, Elkordy M, Ross M, Henderson IC, Budman D, Norton L, Weiss R, Hurd D. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving > 10 axillary lymph nodes (Duke/CALGB 8782). Accepted for presentation. *Proceedings of ASCO* 14: 1995.
39. **Vredenburgh J**, Silva O, de Sombre K, Franklin W, Cirrincione C, Berry D, Peters WP, Bast RC Jr. The significance of bone marrow micrometastases for patients (PTS) with breast cancer and >10+ lymph nodes treated with high-dose chemotherapy and hematopoietic support. Accepted for presentation. *Proceedings of ASCO* 14: 1995.
40. Crews JR, **Vredenburgh J**, Bigner S, Hussein A, Rubin P, Elkordy M, Ross M, Mills L, Penley C, Gockerman J, Peters WP. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after high-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT). Accepted for presentation. *Proceedings of ASCO* 14: 1995.

41. Fisher D, Sherrill GB, Hussein AM, Rubin P, **Vredenburgh JJ**, Ross M, Elkordy MA, Peters WP. Thrombotic angiopathy (TMA) as a complication of high-dose chemotherapy (HDC) for breast cancer. Accepted for presentation. Proceedings of ASCO 14: 1995.
42. **Vredenburgh J**, Petros WP, Hussein A, Ross M, Rubin P, Elkordy M, Coniglio D, Matters L, Dukelow K, Gilbert C, Peters WP. A phase I trial of high-dose ifosfamide (I), carboplatin (Ca), and melphalan (M) (ICaM) with hematopoietic support (HS) for advanced metastatic breast cancer (MBC). Accepted for presentation. Proceedings of ASCO 14: 1995.
43. Hussein A, Petros W, Ross M, **Vredenburgh J**, Affronti M, Jones R, Shpall E, Rubin P, Elkordy M, Gilbert C, Soper J, Berchuck A, Clarke-Pearson D, Peters WP. Phase I/II study of high-dose cyclophosphamide (CPA), Cisplatin (cDDP), and thiotepa (TT) with autologous bone marrow support (ABMS) and granulocyte colony-stimulating factor (G-CSF)-primed peripheral blood progenitor cells (PBPCs) in advanced cancer patients. Proceedings of the ASCO14: 967, 1995.
44. Rubin P, Petros W, **Vredenburgh J**, Hussein A, Elkordy M, Ross M, Peters WP. Cyclophosphamide-induced cardiomyopathy following high-dose chemotherapy. Proceedings of ASCO 14: 968, 1995.
45. Tyler C, DeSombre K, **Vredenburgh JJ**, Peters WP, Bast RC Jr. Two-color immunofluorescence tumor cell detection in immunomagnetically purged stage IV breast samples. Journal of Hematotherapy, vol 4 (3), 245 (#168), 1995.
46. DeSombre K, Tyler CL, Silva O, Cook M, **Vredenburgh JJ**, Peters WP, Bast RC Jr. A comparison of immunohistochemistry, two-color immunofluorescence and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. Journal of Hematotherapy, vol 4 (3), 216 (#82), 1995.
47. Heimer M, Tyler C, **Vredenburgh JJ**, Peters WP, Bast RC Jr. The effect of immunomagnetically purged peripheral blood progenitor cells on bone marrow reconstitution. Journal of Hematotherapy vol. 4 (3), 246 (#174), 1995.
48. Hussein A, Plumer M, **Vredenburgh JJ**, Smith N, Fishman B, Matters L, Affronti ML, Coniglio D, Elkordy M, Rubin P, Ross M, Gilbert C, Petros WP, Peters WP. High Dose Chemotherapy (HDC) with Cyclophosphamide ©, Cisplatin (P), and BCNU (B) (CPB) and Autologous Bone Marrow (ABM) and Peripheral Blood Progenitor Cells (PBPCs) for Stage II/III Breast Cancer Involving 4-9 Axillary Lymph Nodes. Proceeding of ASCO vol 15, 1026, 1996.
49. Tyler CL, **Vredenburgh JJ**, Heimer M, Bast RC Jr, Peters WP. Breast cancer cells are effectively purged from peripheral blood progenitor cells using an immunomagnetic technique. Clin Cancer Res 2(1):81-86, 1996.

50. **Vredenburgh J**, Hussein A, Rubin P, Elkordy M, Tyler C, Heimer M. High Dose Chemotherapy and Immunomagnetically Purged Peripheral Blood Progenitor Cells and Bone Marrow for Metastatic Breast Carcinoma. Proceeding of ASCO vol 15, 983, 1996.
51. Gilbert C, Kondisko HA, Petros WP, Hussein AM, Elkordy M, Rubin P, Peters WP, **Vredenburgh JJ**. Elevated Liver Function Tests (LFTs) Associated with Filgrastim (G-CSF) Priming and Leukapheresis of Peripheral Blood Progenitor Cells. Proceeding of ASCO vol 15, 1025, 1996.
52. Rubin P, Reisner E, **Vredenburgh JJ**, Hussein AM, Elkordy M, Gilbert C, Petros WP, Peters WP. Platelet Alloimmunization (ALM) During High Dose Chemotherapy (HDC). Proceeding of ASCO vol 15, 984, 1996.
53. Peters WP, Jones RB, **Vredenburgh JJ**, Shpall EJ, Hussin A, Elkordy M, Rubin P, Ross M, Berry DB. A Large Prospective, Randomized Trial of High Dose Combination Alkylating Agents (CPB) with Autologous Cellular Support (ABMS) as Consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proceeding of ASCO vol. 15, 149, 1996.
54. Petros W, **Vredenburgh JJ**, Hussein A, Rubin P, Elkordy M, Gilbert C, Colvin OM. Retrospective Analysis and Prospective Strategies for Individualized Delivery of High-Dose Chemotherapy. Presented to NC Cancer Research Symposium, 1996.
55. Hussein A, Plumer M, **Vredenburgh J**, Smith N, Fishman B, Matters L, Affronti ML, Coniglio D, Elkordy M, Rubin P, Ross M, Gilbert C, Petros WP, Peters WP, Colvin OM. High-Dose Chemotherapy (HDC) with Cyclophosphamide ©, Cisplatin (P), and BCNU (B) (CPB) and Autologous Bone Marrow (ABM) and Peripheral Blood Progenitor Cells (PBPCS) for Stage II/III Breast Cancer Involving 4-9 Axillary Lymph Nodes. Presented at NC Cancer Research Symposium, 1996.
56. Hussein A, **Vredenburgh J**, Elkordy M, Rubin P, Fisher D, Canales R, Petros W, Gilbert C, Peret N, Dykstra K, Loewy J, Kaye J, Peter WP. Randomized, Placebo-Controlled Study of Recombinant Human Interleukin Eleven (Neumega™ rhIL-11 Growth Factor) in Patients with Breast Cancer following high-dose chemotherapy with autologous Hematopoietic Progenitor Cells (AHPC) Support. Submitted for Presentation during the 25th Annual Meeting of the International Society for Experimental Hematology, New York, NY, 1996.
57. Hussein A, **Vredenburgh JJ**, Elkordy M, Gilbert C, Petros WP. Protein A Apheresis Therapy for Transplant Induced Thrombotic Microangiopathy. Blood, supplement 1, vol. 88 10:1648, 1996.
58. **Vredenburgh JJ**, Rubin P, Elkordy M, Crews J, Peters WP, Legrand S, DeFusco P.

Secondary Myelodysplasia (MDS)/ Acute Leukemia (AL) after High Dose Chemotherapy for Metastatic Breast Cancer. *Blood*, supplement 1, vol. 88 10:1034, 1996.

59. Hussein AM, Fisher D, **Vredenburgh JJ**, Rubin P, Elkordy M, Peters WP, Peret N, Dykstr K, Kaye, JA. Phase 2 Trial of Neumega rhII-11 in Patients with Breast cancer After High dose chemotherapy with bone marrow and peripheral blood stem cell support. *Blood*, suppl. 1, vol. 88, 10:1189, 1996.
60. Bearman SI, **Vredenburgh JJ**, Cagnoni PJ, Ross M, Shpall EJ, Jones RB. High Dose Chemotherapy with Autologous Hematopoietic Progenitor Cell Support for Patients with Breast Cancer who Failed Previous Stem Cell-Supported Therapy. *Proceeding of ASCO (16)*, 411, 1997.
61. Petros WP, Broadwater G, Berry D, Jones RB, **Vredenburgh JJ**, Gilbert CJ, Colvin OM, Peters WP. Correlation of High Dose Cyclophosphamide (CPA), Cisplatin (CDDP), and Carmustine (BCNU) Pharmacokinetics (PK) to Response and Toxicity in Patient with Primary Breast Cancer. *Proceeding of ASCO (16)*, 56, 1997.
62. **Vredenburgh J**, Tyer C, Broadwater G, Berry D., Desombre K, Silva O. The Incidence and Significance of Tumor Cell Contamination of the Hematopoietic Support from Patients with Breast Cancer Treated with High Dose Chemotherapy. *Proceedings of ASCO (16)*, 338, 1997.
63. Lundell BI, Tyer C, DeSombre K, **Vredenburgh JJ**, Smith AK. Ex-Vivo Perfusion Culture Expansion of Tumor Positive Bone Marrow from Breast Cancer Patients Results in Passive Purging During the Culture Period. *Blood (vol. 90):10*, abst. 951, 1997.
64. Jamieson TA, Carter DL, Pronitz LR, **Vredenburgh JJ**, Marks LB. Predictors for Pneumonitis during local-regional radiotherapy in patients with advanced breast cancer previously treated with high dose chemotherapy and bone marrow transplant. *Proceedings ASTRO*, 1997.
65. Abruzzese E, Radford JE, Miller JS, **Vredenburgh JJ**, Rao PN, Pettenati MJ, Cruz JM, Perry JJ, Amadori S, Hurd DD. Detection of abnormal pre-transplant clones in progenitor cells of patients who developed Myelodysplasia after myeloablative Therapy. *Blood (vol 90):10*, abst. 2625, 1997.
66. Petros W, **Vredenburgh J**, Colvin OM, Long G, Rizzieri D, Smith C, Gilbert C, Chao N. Modification of the High-Dose Stamp 1 chemotherapy regimen to evaluate the potential for individualization of BCNU Systemic Exposure (AUC). *Proceedings ASCO 1998*.
67. **Vredenburgh J**, Rizzieri D, Greenberg C, Long G, Smith C, Petros W, Gilbert C, Blackwell K, Peters K, Congilio D, Affronti ML, Brady C, Chao NJ. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in

patients with metastatic breast cancer. Proceedings of ASCO (17)697, 1998.

68. **Vredenburgh JJ**, Heimer M, Tyer C, Tepperberg M, Long G, Rizzieri D, Smith C, Affronti ML, Brady C, Coniglio D, Gilbert C, Petros WP, Chao NJ. Elimination of breast cancer cells from Peripheral Blood Progenitor Cell (PBPC) collections with immunomagnetic CD34 selection. Proceedings of ASCO (17) 698, 1998.
69. Gilbert C, **Vredenburgh JJ**, Rizzieri D, Long G, Loftis J, Coniglio D, Affronti ML, Chao NJ. The Effect of G-CSF on Docetaxel (Taxotere) Associated Neutropenia during Therapy for Breast Cancer. Proceedings of ASCO (17) 352, 1998.
70. Smith AK, Madalam RK, Maluta JR, Lundell BI, **Vredenburgh JJ**, Douville J, Armstrong RD, Stiff PJ. GMP Clinical Cell Production System: Clinical Engraftment and Tumor Purging During *ex vivo* stem Cell Expansion. Submitted to Fourth International Symposium on High-Dose Chemotherapy and Stem Cell Transplantation in Solid Tumors. April 18-19, Berlin Germany, 1998.
71. Lundell BI, Scott AB, **Vredenburgh JJ**, Smith AK. CD34⁺ Cell Content of G-CSF Mobilized Peripheral Blood Progenitor Cells Correlates with Ex Vivo Expansion Potential. Submitted to ISEH, 1998.
72. Tyer C, **Vredenburgh JJ**. Comparison of four CD34 selection techniques regarding colony forming unit recoveries and spiked tumor depletion. Journal of Hematotherapy (7) P-52, pg. 279, 1998.
73. Tyer C, DeSombre K, **Vredenburgh JJ**. Viability studies of peripheral blood progenitor cells using different storage media, times and temperature. Journal of Hematotherapy (7) P-121, pg. 296, 1998.
74. Tyer C, DeSombre K, **Vredenburgh JJ**. Detection of Breast Tumor Cells using Methycellulose Clonogenic assay technique. Journal of Hematotherapy (7), P-127, pg.298, 1998.
75. Petros WP, **Vredenburgh JJ**, Long GD, Rizzieri D, Smith CA, Chao NJ, Fangmeier J, Colvin OM. 4-Hydroxycyclophosphamide/aldophosphamide systemic exposure during high dose cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Submitted to AACR Annual Meeting April 10-14, 1999.
76. Petros WP, Colvin M, Fangmeier JA, Chao NJ, Smith CA, Rizzieri D, Long GD, **Vredenburgh JJ**. 4-Hydroxy-cyclophosphamide/ aldophosphamide systemic exposure during high dose cyclophosphamide, cisplatin and BCNU in patients with breast cancer." Proc Am Assoc Cancer Res, 1999.
77. Peters W, Rosner G, **Vredenburgh J**, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes

- (LN): Preliminary results of CALGB 9082/SWOB 9114/NCIC MA-13. Proceedings of ASCO 18:1a, #2, 1999.
78. **Vredenburgh JJ**, Long GD, Rizzieri D, Smith CA, Lewis B, McDonald C, Heimer M, Tyer C, Chao NJ: High dose chemotherapy (HDC) with CD34 cellular support for women with poor prognosis metastatic breast cancer (MBC). Proceedings of ASCO 18:49a, #184, 1999.
 79. Long GD, McGaughey DS, **Vredenburgh JJ**, Smith C, Rizzieri D, Folz R, Chao N. Inhaled steroids significantly reduce delayed pulmonary toxicity syndrome following high dose chemotherapy and autologous bone marrow transplantation. Proceedings of ASCO 18:51a, #189, 1999.
 80. Maharaj D, Gouvea JV, Steinberg JP, Gieser PW, Tyer C, **Vredenburgh JJ**. Low incidence of breast cancer cell contamination in peripheral blood progenitor cell (PBPC) products collected with cytoxan/VP16/G-CSF mobilization and large volume leukapheresis to achieve $>10 \times 10^6$ CD34+ cells/kg. Proceedings of ASCO 18:63a, #234, 1999.
 81. Harris LN, Liotcheva V, Broadwater G, **Vredenburgh J**, Ramirez M, Bentley R. Method of measuring ERBB2 (HER-2) give different results in predicting response to high dose chemotherapy in breast cancer patients. Proceedings of ASCO 18:108a, #407, 1999.
 82. Winer EP, Herndon J, Peters WP, Brunatti C, Warren K, **Vredenburgh J**, Schwartz D, Budman D, Shpall EJ, Henderson IC, Norton L, Hurd D, Holland J, Kornblith A. Quality of life in patients with breast cancer randomized to high dose chemotherapy with bone marrow support vs. intermediate dose chemotherapy: CALGB 9066 (Companion Protocol to CALGB 9082). Proceedings of ASCO 18:412a, #1593, 1999.
 83. Morse M, **Vredenburgh J**, Lysterly HK. Dendritic cell (DC) generation before and after high dose chemotherapy (HDC). Proceedings of ASCO 18:442a, #1703, 1999.
 84. Long G, Madan B, Kurtzberg J, Laughlin M, Rizzieri D, Smith C, **Vredenburgh J**, Broadwater G, Chao N. Unrelated umbilical cord blood transplants in adult patients (pts) with hematologic malignancies or genetic disorders. Blood 94(10)(Supplement 1):570a, #2544, 1999.
 85. Mandalam RK, Scott A, Tyer C, **Vredenburgh JJ**, Smith AK. Passive purging of clonogenic breast cancer tumor cells is observed in perfusion based ex vivo bone marrow cultures. Blood 94(10)(Supplement 1):353b, #4804, 1999.
 86. Gasparetto C, Rooney B, Gasparetto M, Morse M, **Vredenburgh J**, Long G, Rizzieri D, Chao N, Loftis J, Smith C. Blood 94(10)(Supplement 1):636a, #2826, 1999.
 87. Goker H, Long GD, Rizzieri DA, Smith CA, Drago S, Morris A, McDonald C, Loftis J, Chao NJ, **Vredenburgh JJ**. Infectious complications in women with metastatic breast

cancer (mbc) treated with high dose chemotherapy (hdc) and CD34 selected hematopoietic support. Blood 94(10)(Supplement 1):368b, #4870, 1999.

88. **Vredenburgh J**, Long G, Blackwell K, Rizzieri D, Smith C, Petros W, Lewis B, Chao NC. Thalidomide modulates vascular endothelial growth factor (VEGF) levels post-autologous peripheral blood progenitor cell transplantation (pbpc) in patients with metastatic breast cancer. Proceedings of the ASCO 19:151a, #599, 2000.
89. Madan B, Broadwater G, Rubin P, Edwards J, Long G, Chao NC, Rizzieri D, Marks L, Affronti ML, Petros W, Peters WP, **Vredenburgh J**. Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (hd-cpb) compared with observation in women with metastatic breast cancer (mbc) and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate (afm): A phase III prospective randomized comparative trial. Proceedings of ASCO 19:49a, #184, 2000.
90. Blackwell KL, Liotcheva V, Haroon ZA, Fung K, Broadwater G, Anderson S, **Vredenburgh J**, Proia A, Greenberg CS, Dewhirst MW, Harris LN. Her-2 gene amplification correlates with higher levels of angiogenesis in primary breast tumors. Proceedings of ASCO 19:649a, #2559, 2000.
91. Petros W, Hopkins P, **Vredenburgh J**, Spruill S, Broadwater G, Colvin M, Marks J, Hall J. Associations between variants in several drug metabolism genes and chemotherapy pharmacokinetics or clinical response. Proceedings AACR March 2001.
92. Peters WP, Rosner G, **Vredenburgh J**, Shpall E, Crump M, Marks L, Cirrincione C, Norton L, Hurd D. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC MA-13. Proceedings ASCO 20:21a (#81), 2001.
93. Neugut AI, **Vredenburgh J**, Weisberg J, Berenson K, Casciano R, Doyle J, Amaya K. Relative efficacy and cost-effectiveness analysis (CEA) of docetaxel versus paclitaxel in the treatment of metastatic breast cancer (MBC). Proceedings of ASCO 20:208b, #2581, 2001.
94. Petros W, **Vredenburgh J**, Fehdrau R, Chao N, Broadwater G, Fangmeier J, Petry N, Coleman E, Colvin M. Evaluation of CYP3A4 metabolic phenotype and cyclophosphamide pharmacokinetics in patients receiving high-dose therapy. Proceedings AACR 2002.
95. Petros W, **Vredenburgh J**, Chao N, Gasparetto C, Long G, Rizzieri D, Broadwater G, Morris A, Colvin M. Feasibility of pharmacokinetic-based dose individualization for cyclophosphamide, cisplatin and carmustine in patients with breast cancer. Proceedings ASCO 21:121a, #408, 2002.
96. Nikcevich D, **Vredenburgh J**, Broadwater G, Ross M, Shpall EJ, Jones RB, Marks L,

Peters WP. Ten-year follow-up after high dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Proceedings ASCO 21:415a, #1657, 2002.

97. Nieto Y, **Vredenburgh J**, Shpall EJ, Bearman S, McSweeney P, Cagnoni P, Elias A, Rabinovitch R, Matthes S, Razook C, Chao N, Jones RB. Pilot phase II study of concurrent administration of trastuzumab and high dose chemotherapy (HDCT) in advanced Her2+ breast cancer. Proceedings ASCO 21:416a, #1663, 2002.
98. Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, Penne K, Sampson J, Shafman T, **Vredenburgh J**, Wong T, Zalutsky M, and Bigner D. Phase I trial results using iodine 131-labeled human-mouse chimeric anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with malignant gliomas. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. Neuro-Oncology 5:395, 2003.
99. Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, Penne K, Sampson J, Shafman T, **Vredenburgh J**, Wong T, Zalutsky M, and Bigner D. Phase I trial results using iodine 131-labeled human-mouse chimeric anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with malignant gliomas. Presentation, SPORE Investigators Workshop, July 8-10, Baltimore, Maryland, 2003.
100. Quinn J, Bigner D, Friedman A, Herndon J, McLendon R, Provenzale J, Rich J, Reardon D, **Vredenburgh J**, Tourt-Uhlig S, Walker W, Stafford-Fox V, Coover C, and Friedman H. Phase II trial of Temodar plus O6-benzylguanine (O6-BG) in the treatment of patients with Temodar- resistant malignant glioma. Abstract TA-29. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:354-355, 2003.
101. Reardon D, Affronti M, Allen D, Baddrudoja M, Beason R, Friedman A, Gururangan S, Jackson S, Quinn J, Rich J, Sampson J, **Vredenburgh J**, Walker A, Ziegler K, Bigner D, and Friedman H. A phase II study of CPT-11 plus celecoxib for adults with recurrent malignant glioma. Abstract TA-31. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:355, 2003.
102. Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, **Vredenburgh J**, Penne K, Sampson J, Shafman T, Wong T, Coleman R, Zalutsky M, and Bigner D. Phase II trial of iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors. Abstract TA-32. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:355, 2003.
103. Desjardins A, Quinn JA, Reardon DA, Rich JN, **Vredenburgh JJ**, Efird C, and Friedman HS. Phase II study of thalidomide and daily Cyclophosphamide for adults

- with malignant glioma. Abstract #1554. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:120S, 2004.
104. Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, Quinn JA, Penne K, **Vredenburgh JJ**, and Bigner DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. Abstract #1569. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:124S, 2004.
 105. Reardon DA, Akabani G, Dowell J, Friedman A, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, **Vredenburgh J**, Penne K, Sampson J, Shafman T, Wong T, Coleman R, Zalutsky M, and Bigner D. Results of a phase II trial with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors. Abstract #5237. Presented at the AACR 95th Annual Meeting, March 27-31, 2004, Orlando, Florida. Proc. Am. Assoc. Cancer Res. 45:1208, 2004.
 106. Badruddoja MA, Reardon DA, **Vredenburgh JJ**, Quinn JA, Rich JN, Desjardins A, Friedman A, Walker A, Bailey P, Jex R, and Friedman HS. Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme. Abstract TA-01. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:369-370, 2004.
 107. Desjardins A, Quinn J, Reardon D, Rich J, **Vredenburgh J**, Friedman A, Tourt-Uhlig S, Badruddoja M, Efirid C, and Friedman HS. Phase II study of thalidomide and daily low-dose cyclophosphamide for adults with anaplastic gliomas. Abstract TA-16. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:373, 2004.
 108. Desjardins A, Reardon D, **Vredenburgh J**, Rich J, Gururangan S, Friedman A, Sampson J, Provenzale J, McLendon R, Herndon II JE, Badruddoja M, Amara J, Tourt-Uhlig S, Newton H, Friedman HS, and Quinn JA. Phase I trial of adults with primary malignant glioma with irinotecan (CPT-11) plus temozolomide (Temodar). Abstract TA-17. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:373-374, 2004.
 109. Quinn JA, Desjardins A, Reardon D, **Vredenburgh J**, Rich J, Gururangan S, Friedman A, Sampson J, Provenzale J, McLendon R, Herndon II JE, Dolan ME, Badruddoja M, Walker A, Tourt-Uhlig S, and Friedman HS. Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus *O*⁶-benzylguanine (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas. Abstract TA-44. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:380, 2004.
 110. Quinn JA, Desjardins A, Reardon D, **Vredenburgh J**, Rich J, Gururangan S, Friedman A, Sampson J, Provenzale J, McLendon R, Herndon II JE, Dolan ME, Badruddoja M,

- Walker A, Tourt-Uhlig S, and Friedman HS. Phase II trial of temozolomide (Temodar) plus *O*⁶-benzylguanine (O6-BG) in the treatment of patients with temodar-resistant malignant glioma. Abstract TA-45. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:380, 2004.
111. Reardon D, Akabani G, Friedman A, Friedman HS, Herndon J, McLendon R, Quinn J, Rich J, **Vredenburgh J**, Penne K, Sampson J, Gururangan S, Shafman T, Wong T, Dowell J, Dunn R, Badruddoja M, Desjardins A, Affronti M, Allen D, Jackson S, Zeigler K, Silverman S, Tourt-Uhlig S, Coleman R, Zalutsky M, and Bigner DD. Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. Abstract TA-46. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:381, 2004.
112. Reardon D, Friedman A, Herndon J, Quinn J, Rich J, **Vredenburgh J**, Badruddoja M, Desjardins A, Sampson J, Gururangan S, Dowell J, Affronti M, Allen D, Jackson S, Zeigler K, Silverman S, Tourt-Uhlig S, Silverman S, Salvado A, Nikolova Z, Bigner DD, and Friedman HS. Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. Abstract TA-47. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:381, 2004.
113. **Vredenburgh JJ**, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Zalutsky M, and Bigner D. Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. Abstract #1510. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:116a, 2005.
114. Friedman HS, Quinn J, Rich J, **Vredenburgh J**, Desjardins A, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, and Reardon D. Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. Abstract #1513. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:117a, 2005.
115. Friedman HS, Quinn J, Rich J, **Vredenburgh J**, Desjardins A, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, and Reardon D. Imatinib mesylate (gleevec) plus hydroxyurea is an effective regimen in the treatment of recurrent malignant glioma. Phase 2 study results. Abstract #1515. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:117a, 2005.
116. Sathornsumetee S, Reardon DA, Quinn J, Rich JN, **Vredenburgh JJ**, Desjardins A, Gururangan S, Lyons P, Salvado A, and Friedman HS. A phase I dose escalation study

of imatinib mesylate plus standard-doses temozolomide in the treatment of patients with malignant glioma. Abstract #1540. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:124s, 2005.

117. Rich JN, Reardon DA, Quinn JA, **Vredenburgh JJ**, Desjardins A, Sathornsumetee S, Gururangan S, Lyons P, Bigner DD, and Friedman HS. A phase I trial of gefitinib (ZD1839) plus repamycin for patients with recurrent malignant glioma. Abstract #1565. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:130s, 2005.
118. Badruddoja MA, Penne K, Desjardins A, Reardon AD, Rich JN, Quinn J, Sznol M, Cahill A, Friedman HS, and **Vredenburgh J**. Phase II study of VNP40101M for adults with recurrent malignant glioma. Abstract #3128. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:223s, 2005.
119. Reardon DA, Quinn J, Rich J, **Vredenburgh J**, Desjardins A, Sathornsumetee S, Salvad A, Nikolova Z, Bigner D, and Friedman H. Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. Abstract 35. Oral Poster Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):291, 2005.
120. Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, **Vredenburgh J**, Zalutsky M, and Bigner D. An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity. Abstract 117. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):311, 2005.
121. Reardon A, Rich J, Quinn J, **Vredenburgh J**, Desjardins A, Sathornsumetee S, Gururangan S, Lyons P, Bigner D, and Friedman H. Phase 1 study results of gefitinib (IRESSA; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma. Abstract 119. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):312, 2005.
122. Desjardins A, **Vredenburgh J**, Badruddoja M, Quinn J, Reardon D, Rich J, Sathornsumetee S, Penne K, Bigner D, and Friedman H. Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma. Abstract 141. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):317, 2005.
123. Desjardins A, Quinn J, Reardon D, Rich J, Sathornsumetee S, **Vredenburgh J**, Walker A, Tourt-Uhlig S, Bigner D, and Friedman H. Temozolomide (TMZ) with O6-benzylguanine (BG) plus CPT-11 in the treatment of recurrent malignant glioma: a phase I trial. Abstract 152. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):320, 2005.
124. Desjardins A, Quinn J, Reardon D, Rich J, Sathornsumetee S, **Vredenburgh J**, Walker A, Tourt-Uhlig S, Bigner D, and Friedman H. Temozolomide (TMZ) with O6-

benzylguanine (BG) for TMZ-resistant malignant glioma: a phase 2 trial. Abstract 471. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. *Neuro-Oncol.* 7(3):401, 2005.

125. **Vredenburgh JJ**, Desjardins A, Herndon JE 2nd, Quinn J, Rich J, Sathornsumetee S, Friedman HS, Reardon D, Gururangan S, Friedman A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Abstract #1506. Presentation: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:59s, 2006
126. **Vredenburgh JJ**, Bohlin C, Reardon DA, Desjardins A, Quinn J, Rich J, Sathornsumetee S, Marks LB, Friedman AH, Friedman HS. Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. Abstract #1539. Presentation: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:67s, 2006.
127. Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, **Vredenburgh JJ**, Desjardins A, Gururangan S, Egorin M, Salvado A, Friedman HS. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. Abstract #1560. Presentation: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:72s, 2006.
128. Quinn JA, **Vredenburgh JJ**, Rich JN, Reardon DA, Desjardins A, Gururangan A, Friedman AH, Lavin K, Sathornsumetee S, Threatt S, Friedman HS. Phase II trial of Gliadel plus 0⁶-benzylguanine (0⁶-BG) for patients with recurrent glioblastoma multiforme. Abstract #1568. Presentation: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:74s, 2006.
129. Desjardins A, Reardon DA, Quinn JA, Rich JN, **Vredenburgh JJ**, Sathornsumetee S, Salvado A, Friedman HS. Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. Abstract # 1573. Presentation: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:76s, 2006.
130. Reardon DA, Quinn JA, Rich JN, **Vredenburgh JJ**, Desjardins A, Sathornsumetee S, Gururangan S, Egorin MJ, Salvado A, Friedman HS. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract # 1580. Presentation: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:77s, 2006.
131. Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, **Vredenburgh JJ**, Friedman AH, Reardon DA, Friedman HS. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. Abstract # 11504. Publication: ASCO Annual Meeting 2006 Proc. *Am. Soc. Clin. Oncol.* 24:593s, 2006.
132. Kirkpatrick J, Desjardins A, **Vredenburgh JJ**, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman AH, Friedman HS. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide:

Study of cases. Abstract # 11522. Publication: ASCO Annual Meeting 2006 Proc. Am. Soc. Clin. Oncol. 24:594s, 2006.

133. Reardon D, Akabani G, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, **Vredenburgh J**, Desjardins A, Sampson J, Gururangan S, Kirkpatrick J, Wong T, Dowell J, Dunn R, Sathornsumetee S, Boulton S, Coleman R, Zalutsky M, Bigner D. Patient-specific murine ¹³¹I-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. Abstract RO-23. Oral presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 489, 2006.
134. Affronti ML, Dowell JM, Herndon 2nd JE, Cahill J, Rich JN, Quinn JA, Reardon DA, **Vredenburgh JJ**, Desjardins A, Gururangan S, Friedman HS. Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy. Abstract TA-01. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 437, 2006.
135. Desjardins A, **Vredenburgh J**, Quinn J, Rich J, Sathornsumetee S, Gururangan S, Friedman A, Reardon D, Friedman H. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and chemotherapy for recurrent malignant glioma patients: Series of cases. Abstract TA-12. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 440, 2006.
136. Desjardins A, **Vredenburgh J**, Quinn J, Rich J, Sathornsumetee S, Friedman A, Reardon D, Friedman H. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide or irinotecan as an upfront treatment in patients with malignant glioma: Study of cases. Abstract TA-13. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 440, 2006.
137. Desjardins A, Quinn JA, Rich JN, **Vredenburgh JJ**, Sathornsumetee S, Gururangan S, Friedman AH, Berg W, Egorin MJ, Salvado A, Friedman HS, Reardon DA. A phase I trial of imatinib (Gleevec), hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract TA-14. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 441, 2006.
138. Quinn JA, Desjardins A, Rich JN, **Vredenburgh JJ**, Reardon DA, Gururangan S, Sathornsumetee S, Walker A, Lavin KN, Birch R, Friedman AH, Friedman HS. Phase I trial of temodar plus O⁶-Benzylguanine 5-day regimen for patients with progressive glioblastoma multiforme. Abstract TA-48. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. Neuro-Oncology, 450, 2006.

139. Sathornsumetee S, Rich JN, **Vredenburgh JJ**, Desjardins A, Quinn JA, Gururangan S, Friedman AH, Egorin MJ, Salvado A, Friedman HS, Reardon DA. Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma. Abstract TA-50. Poster presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. *Neuro-Oncology*, 451, 2006.
140. **Vredenburgh J**, Desjardins A, Herndon 2nd JE, Reardon D, Quinn J, Sathornsumetee S, Gururangan S, Friedman A, Bigner D, Friedman H. Bevacizumab and irinotecan is an effective treatment for malignant glioma. Abstract TA-64. Oral presentation, Society for Neuro-Oncology Eleventh Annual Meeting, Orlando, Florida, November 15-19, 2006. *Neuro-Oncology*, 454, 2006.
141. Desjardins A, Barboriak DP, Herndon 2nd JE, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Friedman HS, **Vredenburgh JJ**. The Duke experience with Bevacizumab (BEV) and Irinotecan (CPT-11) in patients with recurrent malignant glioma: An overview of two trials. Oral presentation, Duke Comprehensive Cancer Center's Annual Meeting, P151, March 12, 2007.
142. Goli KJ, Desjardins A, Herndon 2nd JE, Rich JN, Reardon DA, Quinn JA, Sathornsumetee S, Bota DA, Friedman HS, **Vredenburgh JJ**. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. Abstract #2003, *J Clin Oncol*, 25:18s, 2007.
143. Sathornsumetee S, Rich JN, **Vredenburgh JJ**, Desjardins A, Quinn JA, Gururangan S, Egorin MJ, Salvado AJ, Friedman HS, Reardon DA. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). Abstract #2027, *J Clin Oncol* 25:81s, 2007.
144. Desjardins A, Barboriak DP, Herndon 2nd JE, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman HS, **Vredenburgh JJ**. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). Abstract #2029, *J Clin Oncol* 25:82s, 2007.
145. Quinn JA, **Vredenburgh JJ**, Rich JN, Reardon DA, Desjardins A, Gururangan S, Friedman AH, Carter JH, Threatt S, Freidman HS. Phase II trial of Gliadel plus O⁶-benzylguanic (O⁶-BG) for patients with recurrent glioblastoma multiforme. Abstract #2036, *J Clin Oncol* 25:84s, 2007.
146. Bota DA, Desjardins A, Quinn JA, Rich JN, **Vredenburgh JJ**, Sathornsumetee S, Goli K, Salvado A, Friedman HS, Reardon DA. Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma. Abstract #2053, *J Clin Oncol* 25:88s, 2007.
147. Kirkpatrick J, Desjardins A, Quinn J, Rich J, **Vredenburgh J**, Sathornsumetee S, Gururangan S, Sidor C, Friedman H, Reardon D. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal

dispersion administered orally to patients with recurrent glioblastoma multiforme. Abstract #2065, J Clin Oncol 25:91s, 2007.

148. Affronti ML, Day JM, Herndon 2nd JE, Rich JN, Quinn JA, Reardon DA, **Vredenburgh JJ**, Desjardins A, McLendon RE, Friedman HS. Radiation and concurrent temozolomide followed by rational multi-agent chemotherapy for glioblastoma (GBM) patients. Abstract #2068, J Clin Oncol 25:92s, 2007.
149. Rich JN, Affronti ML, Day JM, Herndon 2nd JE, Quinn JA, Reardon DA, **Vredenburgh JJ**, Desjardins A, Friedman. Overall survival of primary glioblastoma (GBM) patients (pts) receiving Carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. Abstract #2070, J Clin Oncol 25:92s, 2007.
150. Bohlin CW, Reardon DA, Desjardins A, Quinn JA, Rich JN, Bota DA, Goli K, Friedman HS, **Vredenburgh JJ**. Tinzaparin prophylaxis in brain tumor patients. Publication #12506, J Clin Oncol 25:605s, 2007.
151. **Vredenburgh JJ**, Bohlin CH, Reardon DA, Desjardins A, Quinn JA, Rich JN, Bota DA, Goli KJ, Friedman HS, Allen DH. Pilot study of dronabinol for adult patients with primary malignant gliomas. Publication #19607, J Clin Oncol 25:715s, 2007.

Professional Awards and Special Recognitions:

Frank N. Willard, M.D., Award Most Outstanding and Sensitive Physician, St. Francis Hospital and Medical Center, 1986

Tiffany Blake Fellow, Hitchcock Clinic, 1988

Most Compassionate Physician, Dartmouth-Hitchcock Medical Center, 1988

Organizations and Participation:

American Society of Hematology

American Society of Clinical Oncology

American Society of Blood and Marrow Transplantation

Society for Neuro-Oncology

Teaching Responsibilities including Continuing Education:

Director Neuro-Oncology Fellowship Program at Duke University Medical Center

Areas of Research Interests (basic and applied):

1. Primary brain tumors
2. Hypercoagulable states associated with brain tumors

3. CNS complications of solid tumors
4. Supportive care of brain tumor patients
5. Anti-angiogenic therapy for brain tumors

Participation in Academic and Administrative Activities of the University and Medical Center:

Medical Director Stem Cell Cryopreservation Laboratory, 07/90 – 01/02
Medical Director Hillandale Clinical Laboratory, 05/92 – 01/02
Interim Director Bone Marrow Transplant Program, 07/95 – 12/9
Cancer Protocol Review Committee member, 01/91 – 01/01, 06/04-present
Medical Director Pharmacology Laboratory, 07/95 – Present
Clinical Microbiology Users Committee, 06/98 – Present
Cancer Center Users Executive Committee, 06/00 – Present
Medical Director of Clinical Operations, 06/05 – Present